Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
AOD 9604 does not raise blood sugar, does not cause insulin resistance, and does not interfere with tirzepatide insulin-sensitizing effects
This measured approach prevents wasteful spending on peptides that provide marginal benefit for specific circumstances
Its use is investigational, and it is not approved by any regulatory authority for the treatment of any specific medical condition
STAT News reported that FDA has withdrawn its objection to UniQure's Huntingtons disease drug AMT-130, clearing the path for the company to file an accelerated approval application in the third quarter of 2026
The peptide primes tissue to respond more effectively to growth signals from any source
US$ 23.11
US$ 20.61
US$ 22.44
US$ 21.71
US$ 25.17
US$ 26.19
US$ 29.46
US$ 24.26
US$ 24.82
US$ 21.26
